Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification

Deng, Bo; Liu, Fei; Yin, Sineng; Chen, Anping; Xu, Lin; Li, Bo

doi:10.1016/j.clinre.2017.09.004

Cited by 12 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pancreatic NETs had significantly more grade 2 tumours, while the small bowel NETs were more often grade 1 tumours. The differences in overall survival between grade 1 and grade 2 tumours were described in previous studies [2,8]. This study demonstrates a median overall survival of 86 months for patients with metastatic small bowel NETs; due to the chosen study period and censoring of patients, the number of patients in follow-up after 120 months becomes very low.…”

Section: Discussionsupporting

confidence: 64%

“…In some studies, up to 50% of patients reported symptoms for 2 to 5 years prior to diagnosis [3,4]. Due to the relative delay in diagnosis, metastatic disease is present in 25% of patients in population-based studies [1,2,5,6], but in tertiary centers, this figure is 60-80% [7][8][9][10]. Patients with NETs have a good prognosis even in metastatic disease, with the overall 5-year survival reaching 50-70% [2,5,6].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of Sarcopenia and Impact on Survival in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumours

Clement

Leerdam

Jong

et al. 2023

Cancers

View full text Add to dashboard Cite

Sarcopenia in patients with cancer is associated with adverse outcomes such as shorter survival. However, there exists little evidence regarding the prevalence of sarcopenia in patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Patients with a histologically confirmed newly diagnosed metastatic GEP-NET between 2006 and 2018, CT scan, and anthropometric data at diagnosis were included in this study. CT scans were analysed for the presence of sarcopenia and correlated with overall survival (OS). In total, 183 patients, 87 male (48%), with a median age of 62 years (IQR 52–68 years), were included. In 44 patients (24%), there was a pancreas NET, and in 136 patients, there was a small bowel NET (74%). Sarcopenia was present in 128 patients (69%) and unrelated to BMI (median 25.1). There were significant survival differences between patients with pancreatic and small bowel NETs at 86 vs. 141 months, respectively (p = 0.04). For patients with pancreatic NETs, the presence of sarcopenia was independently associated with shorter OS (HR 3.79 95% CI 1.1–13.03, p-value 0.035). A high prevalence of sarcopenia at the time of diagnosis of a metastatic GEP-NET was seen and associated with worse OS in patients with pancreatic NETs. Further research should focus on how to reverse sarcopenia and its impact on OS and/or quality of life.

show abstract

Section: Discussionsupporting

confidence: 64%